Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00082875 · ClinicalTrials.gov registry record · Phase 2
Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT00082875: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00082875 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 56 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00082875, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
This randomized phase II trial is studying how well cilengitide works in treating patients with unresectable stage III or stage IV melanoma. Cilengitide may stop the growth of melanoma by stopping blood flow to the tumor.
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG cilengitide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2004-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00082875
The ClinicalTrials.gov registry entry for NCT00082875 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00082875 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00082875 about?
NCT00082875 is a clinical study titled "Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma". This randomized phase II trial is studying how well cilengitide works in treating patients with unresectable stage III or stage IV melanoma. Cilengitide may stop the growth of melanoma by stopping blood flow to the tumor.
What is the current status of trial NCT00082875?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2004-03.
What interventions are being tested in trial NCT00082875?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), cilengitide (DRUG).
Who is sponsoring clinical trial NCT00082875?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.